A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma

Onkologie

Volumn 34, Issue 7, 2011, Pages 368-376

  Van Malenstein, Hannah ^a   Maleux, Geert ^a   Vandecaveye, Vincent ^a   Heye, Sam ^a   Laleman, Wim ^a   Van Pelt, Jos ^a   Vaninbroukx, Johan ^a   Nevens, Frederik ^a   Verslype, Chris ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Chemoembolization; Doxorubicin; Drug eluting beads; Hepatocellular carcinoma; Pharmacokinetics

Indexed keywords

DOXORUBICIN; MICROSPHERE; SUPERABSORBENT POLYMER MICROSPHERE; UNCLASSIFIED DRUG;

ADULT; ADVERSE DRUG REACTION; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; CHEMOEMBOLIZATION; CHOLECYSTITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FEVER; DRUG HYPERSENSITIVITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER FAILURE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PHASE 2 CLINICAL TRIAL; POST EMBOLIZATION SYNDROME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; STOMATITIS; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 79960188599     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000329602     Document Type: Article

References (41)

1. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003;362:1907-1917. (Pubitemid 37518510)
2. Bruix J, Sala M, Llovet JM: Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127(5 suppl 1):S179-188. (Pubitemid 39423386)
3. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al.: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739. (Pubitemid 34607087)
4. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al.: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35: 1164-1171. (Pubitemid 34454013)
5. Geschwind JF, Ramsey DE, Cleffken B, van der Wal BC, Kobeiter H, Juluru K, et al.: Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol 2003;26:111-117. (Pubitemid 36919549)
6. Johnson PJ, Kalayci C, Dobbs N, Raby N, Metivier EM, Summers L, et al.: Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol 1991;13:120-127.
7. Buijs M, Vossen JA, Frangakis C, Hong K, Georgiades CS, Chen Y, et al.: Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization -single-center experience. Radiology 2008; 249:346-354.
8. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-314.
9. Wang JJ, Cortes E, Sinks LF, Holland JF: Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease. Cancer 1971;28:837-843.
10. Khankan AA, Osuga K, Hori S, Morii E, Murakami T, Nakamura H: Embolic effects of superabsorbent polymer microspheres in rabbit renal model: comparison with tris-acryl gelatin microspheres and polyvinyl alcohol. Radiat Med 2004;22:384-390. (Pubitemid 40144015)
11. Osuga K, Khankan AA, Hori S, Okada A, Sugiura T, Maeda M, et al.: Transarterial embolization for large hepatocellular carcinoma with use of superabsorbent polymer microspheres: initial experience. J Vasc Interv Radiol 2002;13:929-934.
12. Grosso M, Vignali C, Quaretti P, Nicolini A, Melchiorre F, Gallarato G, et al.: Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol 2008;31:1141-1149.
13. Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S, et al.: Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 2008;31:269-280.
14. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al.: Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46:474-481. (Pubitemid 46201723)
15. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al.: Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41-52.
16. Lee KH, Liapi EA, Cornell C, Reb P, Buijs M, Vossen JA, Ventura VP, Geschwind JF: Doxorubicin-loaded QuadraSphere microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer. Cardiovasc Intervent Radiol 2010;33:576-582.
17. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al.: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430. (Pubitemid 32844200)
18. Georgiades CS, Hong K, DAngelo M, Geschwind JF: Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005;16:1653-1659. (Pubitemid 44431162)
19. Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, Shi M: Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011;18:413-420.
20. Kim JH, Yoon HK, Kim SY, Kim KM, Ko GY, Gwon DI, Sung KB: Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther 2009;29:1291-1298.
21. Liu DM, Salem R, Bui JT, Courtney A, Barakat O, Sergie Z, et al.: Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 2005;16:911-935. (Pubitemid 40993515)
22. Kummerle A, Krueger T, Dusmet M, Vallet C, Pan Y, Ris HB, et al.: A validated assay for measuring doxorubicin in biological fluids and tissues in an isolated lung perfusion model: matrix effect and heparin interference strongly influence doxorubicin measurements. J Pharm Biomed Anal 2003;33:475-494. (Pubitemid 37206472)
23. Arbuck SG, Ivy SP, Setser A, et al.: The Revised Common Toxicity Criteria: Version 2.0. CTEP Website, //ctep.info.nih.gov.
24. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al.: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
26. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442. (Pubitemid 36152543)
27. Maleux G, van Malenstein H, Vandecaveye V, Heye S, Vaninbroukx J, Nevens F, et al.: Transcatheter chemoembolization of unresectable hepatocellular carcinoma: current knowledge and future directions. Dig Dis 2009;27:157-163.
28. Raoul JL, Heresbach D, Bretagne JF, Ferrer DB, Duvauferrier R, Bourguet P, et al.: Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 1992;70:585-590.
29. Liapi E, Lee KH, Georgiades CC, Hong K, Geschwind JF: Drug-eluting particles for interventional pharmacology. Tech Vasc Interv Radiol 2007;10:261-269. (Pubitemid 351902189)
30. Poggi G, Quaretti P, Minoia C, Bernardo G, Bonora MR, Gaggeri R, et al.: Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors. Anticancer Res 2008;28:3835-3842.
31. Vandecaveye , De Keyzer F, Verslype C, Op de Beeck K, Komuta M, Topal B, et al.: Diffusionweighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma. Eur Radiol 2009;19:2456-2466.
32. Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL: A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002;94:1747-1752. (Pubitemid 34241113)
33. Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC: Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 2001;12:321-326. (Pubitemid 32217030)
34. Patel NH, Hahn D, Rapp S, Bergan K, Coldwell DM: Hepatic artery embolization: factors predisposing to postembolization pain and nausea. J Vasc Interv Radiol 2000;11:453-460. (Pubitemid 30214840)
35. Wagnetz U, Jaskolka J, Yang P, Jhaveri KS: Acute ischemic cholecystitis after transarterial chemoembolization of hepatocellular carcinoma: incidence and clinical outcome. J Comput Assist Tomogr 2010;34:348-353.
36. De Baere T, Roche A, Amenabar JM, Lagrange C, Ducreux M, Rougier P, et al.: Liver abscess formation after local treatment of liver tumors. Hepatology 1996;23:1436-1440. (Pubitemid 26181226)
37. Kim HK, Chung YH, Song BC, Yang SH, Yoon HK, Yu E, et al.: Ischemic bile duct injury as a serious complication after transarterial chemoembolization in patients with hepatocellular carcinoma. J Clin Gastroenterol 2001;32:423-427. (Pubitemid 32378276)
38. Kwok PC, Lam TW, Chan SC, Chung CP, Wong WK, Chan MK, et al.: A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma. J Hepatol 2000;32:955-964. (Pubitemid 30368089)
39. Castells A, Bruix J, Ayuso C, Bru C, Montanya X, Boix L, et al.: Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. J Hepatol 1995;22:410-415.
40. Geschwind JF, Kaushik S, Ramsey DE, Choti MA, Fishman EK, Kobeiter H: Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. J Vasc Interv Radiol 2002;13:1163-1166. (Pubitemid 35332903)
41. Song SY, Chung JW, Han JK, Lim HG, Koh YH, Park JH, et al.: Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol 2001;12:313-320.